The EverLife Capital Brief · October 29, 2026
What's Moving From Lab To Humans For Liver Repair
About 1 in 3 U.S. adults may have fatty liver disease, depending on how it is measured. Even a healthy liver changes with age: in older adults it can be 20% to 40% smaller, blood flow through it 35% to 50% lower, and its ability to regrow declines (World Journal of Gastroenterology review).
That makes liver repair a field worth watching for many of us as we age, and one companies are racing to build. The treatments below target specific diseases; whether they help healthy aging is not yet known. Here is what is moving from the lab to people, and how strong the evidence really is.
💊 Approved Treatments
Madrigal's Pill Improved Liver Scarring In About 1 In 4 Treated Patients
In Rezdiffra's 966-patient trial, 24% to 26% of patients on the drug had at least a one-stage improvement in scarring after 52 weeks without worsening disease activity, versus 14% on placebo. Most treated patients did not reach that bar, and diarrhea and nausea were more common on the drug. The FDA granted accelerated approval in March 2024 for certain adults with MASH (an inflammatory form of fatty liver disease) with moderate-to-advanced scarring and no cirrhosis, alongside diet and exercise. More than 50,000 patients were taking it as of the company's July 2026 report. Shown in: people. MDGL: $434.24 and market cap about $10.0B (Oct 23 close); cash $838.9M (June 30, 2026).
SPONSORED · EverLife Capital earns a referral fee if you subscribe through this link
Make Room For Healthier Habits In Your Inbox
Want simple, practical ideas for healthier everyday living? Healthy Living Daily is a free newsletter with tips you can read when it suits you. Unsubscribe anytime.
Wegovy Also Has A Liver-Disease Approval
Wegovy injection received accelerated FDA approval in August 2025 for adults with MASH and moderate-to-advanced scarring, without cirrhosis, alongside diet and exercise. At 72 weeks, 37% of patients had improved scarring without worsening MASH, versus 22% on placebo. These figures come from a separate trial, so they cannot be compared head to head with Rezdiffra. Shown in: people.
🧪 Experimental Liver Support
A Bioengineered Liver Is Being Tested Outside The Body
United Therapeutics' miroliverELAP is designed to give a failing liver temporary support from outside the body. In a small Phase 1 study, all 5 patients with acute liver failure survived the treatment period. There was no comparison group, so it does not show the device saved them, and it remains investigational. Shown in: people (5 patients, no comparison group). UTHR: $592.84 and market cap about $25.4B (Oct 26 close); cash and investments $3.8B (June 30, 2026).
Could A Pig Liver Provide Temporary Support?
In an experiment reported in 2024, a brain-dead donor's blood ran through a gene-edited pig liver outside the body for 72 hours. In April 2025, eGenesis and OrganOx announced FDA clearance for a trial of up to 20 patients with acute-on-chronic liver failure who cannot get a transplant. Clearance to test does not show it works. Shown in: one brain-dead donor. eGenesis is private.
🧬 Growing Tissue And Reprogramming Cells
Could Lymph Nodes Grow Extra Liver Tissue?
LyGenesis places donor liver cells in lymph nodes to grow functioning liver tissue, which it has shown in pigs. In March 2025, a safety board reviewed the first 4 patients and recommended continuing at a higher dose. That supports further testing, not a proven benefit in people. Shown in: pigs; an early safety review in people. LyGenesis is private.
Can Cell Reprogramming Help A Damaged Liver?
Life Biosciences' liver program, ER-300, improved liver fat and injury markers in a mouse model of MASH, according to the company. Its separate eye program, ER-100, is in a first human trial: in October 2026, the company reported it was well tolerated in its first 3 glaucoma patients through 56 days. The liver work is still preclinical, and the eye results do not show the approach can repair human livers. Shown in: mice (liver); 3 people (eye, safety). Life Biosciences is private.
EverLife Capital Members
Look Beyond The Breakthrough Headlines
Members get plain-English analysis of each company we cover: who the results were shown in, and the warning signs to check before putting money in. You can also ask us to analyze the companies you care about. Free for 14 days.
Biotechnology investments can lose substantial value, including your entire investment. Clinical success or regulatory approval does not guarantee commercial success or investment returns.
⏳ A Result To Watch
Inventiva Expects Phase 3 Results This Quarter
Inventiva expects results from its Phase 3 lanifibranor trial in Q4 2026, according to its September update. The last of 1,009 patients completed the final 72-week visit in September. Cash, equivalents and short-term deposits were €233.9M (about $262M) at June 30, which the company forecasts will last into Q2 2027. Shown in: results not out yet. IVA: $3.66 and market cap about $880M (Oct 26).
🔎 Also On The Radar
Satellite Bio: the FDA cleared it in August 2026 to begin testing a liver cell therapy in infants with severe urea cycle disorders. That is permission to study, not approval to sell.
Cytotheryx: a Mayo Clinic spinout; a $60M Series A was announced in January 2026 for its preclinical liver cell therapies.
New patent (Aug 25, 2026): United Therapeutics' Revivicor was granted US 12714077 for a multi-gene-edited pig for organ transplants. A patent is not clinical proof.
Questions or ideas? Just hit reply.
Talk soon,
Eric
Which Organ Should I Cover Next?
Want to advertise in EverLife Capital? Reach readers focused on aging well and longevity science. Email [email protected]. We do not accept payment, directly or through agencies, from companies we cover.
EverLife Capital publishes general educational research, not personalized investment or medical advice, and nothing here is a recommendation to buy or sell any security. EverLife Capital earns a referral fee when readers subscribe to Healthy Living Daily through this issue; no company covered in this issue paid for coverage, directly or indirectly. Early clinical findings and animal results may not lead to lasting benefits for patients, and clinical progress does not guarantee investment returns. Treatment decisions belong with a qualified clinician. Prices are dated where shown and may have changed. EverLife Capital is published by Consult US, LLC. Eric Pemper does not hold positions in companies mentioned. Some research and summaries are prepared with AI assistance and reviewed before publication.
